Camlin Fine Sciences Share Price

    NSE
    210.50
    +3.70 (1.92%)
    CAMLINFINE • 20 Aug, 2025 | 01:22 PM
    Buy

    1Y Annualised Return

    101.55%

    3Y Annualised Return

    21.37%

    5Y Annualised Return

    18.62%

    10Y Annualised Return

    8.91%

    The current prices are delayed, login or Open Demat Account for live prices.

    Camlin Fine Sciences Stock Performance

    1W Return3.11
    1Y Return106.25
    Today's Low206.3
    Prev. Close206.80
    Mkt Cap (Cr.)3,886.21
    1M Return-28.06
    3Y Return78.87
    52-Week High333.3
    Open209.00
    PE Ratio216.25
    6M Return39.17
    Today's High214
    52-Week Low93.4
    Face Value1

    Camlin Fine Sciences Company background

    Founded in: 1993
    Managing director: Ashish S Dandekar
    Camlin Fine Sciences Limited was originally incorporated on November 30, 1993 as a Private Limited Company with the name of Camlicon Consultants Private Limited. On June 1, 2006, the Company name was changed from Camlicon Consultants Private Limited to Camlin Fine Chemicals Private Limited. As per the Scheme of Arrangement, the Fine Chemicals Division of Camlin Limited got demerged and transferred to the Company effective from July 01, 2006. On August 11, 2006, the Company status was converted into Public Limited Company and the name was changed to Camlin Fine Chemicals Limited. W.e.f. 27th August, 2011 name of the Company was changed from Camlin Fine Chemicals Limited to Camlin Fine Sciences Limited.The Company is one of the Indias leading manufacturers and exporters of Bulk Drugs, Fine Chemicals and Food Grade products. It manufactures active pharmaceutical ingredients (APIs), food antioxidants and sweeteners. They operate in two business divisions, namely Food Ingredients Division and Industrial products Division. The companys products have applications in processed foods, edible oils, paints, polymers, alternative fuels (biodiesel), rubber, health, and pharmaceuticals.The company has a strong research and development which is focused on bringing in continual improvements on process and products, backward integration and developing innovative products. The research and development is equipped with comprehensive and updated instrumentation for conducting quality analysis, stability studies. The research and development also is equipped to conduct application studies on stability index of edible oils and Biodiesel.In April 2006, the main object of the Company was altered to enable the Company to pursue business in Fine Chemicals. They launched a new product namely, Sucralose which is a synthetic sweetener with large demand and attractive price.The company entered into a joint venture with Viachem LLC USA on 51:49 basis and set up a company namely, Dulcette Technologies LLC for marketing Sucralose, Aspartame and AcesulfameK and their blends in USA, Canada and Mexico. In March 30, 2007, the equity shares of the company were listed on the Bombay Stock Exchange (BSE).During the year 200708, the company increased the production capacity of Chemical Chemical Products from 1,636 Ltrs/Kgs to 2,476 Ltrs/Kgs. The company acquired the control of Sangam Laboratories Ltd by acquiring 60% of the paid up equity share capital of the company. They invested Rs 5 lakh for controlling interest in the Equity Share Capital of Chemolutions Chemicals Ltd. In February 2008, the company entered into a joint venture agreement with Advanced Aerospace Technologies Inc., USA to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets. During the year 200809, the company expanded the production capacity of Chemical Chemical Products from 2,476 Ltrs/Kgs to 2,548 Ltrs/Kgs. The company invested Rs 25.50 lakh in Fine Lifestyle Brands Ltd and Rs.5.10 lakh in Fine Renewable Energy Ltd, which represents 51% of equity share capital of each of them. They further invested Rs 92.32 lakh in the share capital of their present subsidiaries, namely Sangam Laboratories Ltd, Chemolutions Chemicals Ltd and Dulcette Technologies LLC, USA.During the year 200910, the company expanded the production capacity of Chemical Chemical Products from 2,458 Ltrs/Kgs to 3,500 Ltrs/Kgs. They are entering the field of Bio technology products and first patented, biotechnology based Natural shelf life enhancing formula for increasing shelf life of Natural farm produce, like fruits, vegetables and flowers.During the year 2011, Chemolutions Chemicals Limited, Fine Lifestyle Brands Limited and Fine Renewable Energy Limited ceased to be subsidiaries of the Company. The Honble High Court Bombay, vide order dated 21st April, 2011 approved Scheme of Amalgamation for merger of Sangam Laboratories Limited, a 100% owned subsidiary with the Company. The establishment of two major business divisions, namely, Food and Industrial Products was completed. The Company expanded its manufacturing capacity of the food antioxidants, Ascorbyl Palmitate, TBHQ and BHA in 201213. In January 2016, it started operations in Central America with the launch of CFS Antioxidantes De Mexico, S.A. de C.V., a 100% subsidiary of Camlin Fine Sciences Ltd., acquired 65% stake in Dresen Qumica S.A.P.I de C.V, a leading food and feed blend company in Mexico launched CFS North America, LLC, a 100% owned subsidiary of CFS for manufacturing and selling of customised antioxidant blends launched Evanil, ethyl vanillin for food and bakery industry.On 15th April, 2016, a 100% wholly owned subsidiary CFS International Trading (Shanghai) Ltd. was incorporated in China (Shanghai) pilot free trade zone to manufacture and deal in speciality chemicals. On 22nd March, 2017, Chemolutions Chemicals Limited (CCL) allotted 62,67,003 equity shares on preferential basis to the Company. Post allotment, the shareholding of Company in CCL was 94.08% and CCL became the subsidiary of the Company. In July 2017, Company through its wholly owned stepdown subsidiary viz. CFS Europe S.p.A. acquired 51% stake in CFS Wanglong Flavours (Ningbo) Co. Ltd. erstwhile Ningbo Wanglong Flavors and Fragrances Company Limited. In April 2018, Company signed a joint venture contract with Pahang Pharma (S) Pte. Ltd., Singapore (Pahang) for incorporating a holding company, shareholding in the proportion of 51:49, named CFS Pahang Asia Pte. Ltd. in Singapore.In 2019, the Company reverse merged its wholly owned subsidiary in Mauritius viz., CFCL Mauritius Private Limited into CFS Europe Spa, Italy effective 25th June, 2019 and resultant to this merger, CFS Europe Spa became a whollyowned subsidiary. The reverse merger of CFS Antioxidnates De Mexico De CV with Dresen Quimica SAPI De CV was effective 31st January, 2019 and resultant to reverse merger, CFS Antioxidantes De Mexico S.A. de. C.V. ceased to be the whollyowned subsidiary of the Company from the aforementioned date. As a part of this initiative, Company acquired a company situated in Southern part of India, namely, AlgalR Nutrapharms Private Limited (AlgalR) which manufactures oils containing Omega 3 Fatty Acids. The company embarked upon its largest greenfield expansion in 2018 in Dahej, Gujarat for a greentechnologybased DiPhenol plant for a 10,000 MT DiPhenol facility. And in September 2020, it announced the commercial production of Hydroquinone and Catechol.During the financial year 202122, AlgalR NutraPharms Private Limited and CFS De Mexico Blends SAPI De CV became subsidiaries and Fine Lifestyle Brands Limited has ceased to be a Associate of the Company.The Company initiated the commercial production of Vanillin and Ethyl Vanillin in Dahej in January, 2023 in FY 2024.

    Camlin Fine Sciences Financial Highlights


    Camlin Fine Sciences reported a Q1 FY 2025-26 revenue of ₹423.55 crore, up 3.2% YoY, with net profit decreased -146.7% to ₹-5.14 crore. For the full year FY20252026, revenue reached ₹1680.98 crore and profit touched at ₹48.96 crore. As of Jun '25, Camlin Fine Sciences’s market capitalisation stood at ₹3,886.21 crores. Shareholding as of Jun '25 shows promoters holding 49.1%, with FIIs at 2.9%, DIIs at 4.1%, and public at 43.9%.

    As of 20 Aug, 2025, Camlin Fine Sciences share price is ₹210.5. The stock opened at ₹209 and had closed at ₹206.8 the previous day. During today’s trading session, Camlin Fine Sciences share price moved between ₹206.30 and ₹214.00, with an average price for the day of ₹210.15. Over the last 52 weeks, the stock has recorded a low of ₹93.40 and a high of ₹333.30. In terms of performance, Camlin Fine Sciences share price has increased by 39% over the past six months and has increased by 101.55% over the last year.
    Read More
    Camlin Fine Sciences SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years
    Total Investment of ₹65,00,000
    Would have become ₹1,12,79,108 (+73.52%)
    Daily SIP of 25,000 would have become 1,12,79,108 in 1 year with a gain of 47,79,108 (+73.52%)
    View details of Market Depth

    Camlin Fine Sciences Fundamental

    Market Cap (in crs)

    3,886.21

    Face Value

    1

    Turnover (in lacs)

    344.66

    Key Metrics

    Qtr Change %
    36.84% Fall from 52W High
    5.5
    Dividend yield 1yr %
    0

    Camlin Fine Sciences Key Financials

    View more
    Loading chart...
    Loading chart...
    Loading chart...
    Loading chart...
    Camlin Fine Sciences Quarterly Revenue
    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    423.55 Cr
    437.46 Cr
    433.49 Cr
    422.97 Cr
    395.85 Cr
    Camlin Fine Sciences Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    1680.98 Cr
    1628.62 Cr
    1687.36 Cr
    1445.12 Cr
    1192.09 Cr
    1052.58 Cr
    Camlin Fine Sciences Quarterly Net Profit/Loss
    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    -5.14 Cr
    20.96 Cr
    -5.62 Cr
    -116.61 Cr
    -34.65 Cr
    Camlin Fine Sciences Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    48.96 Cr
    -104.88 Cr
    39.81 Cr
    60.51 Cr
    65.36 Cr
    29.83 Cr

    Camlin Fine Sciences Result Highlights

    • Camlin Fine Sciences Ltd reported a 6.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.6%.

    • Its expenses for the quarter were down by 3.1% QoQ and up 3.8% YoY.

    • The net profit decreased 86.9% QoQ and decreased 69.2% YoY.

    • The earnings per share (EPS) of Camlin Fine Sciences Ltd declined at 0.5 during Q1 FY 2025-26.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Camlin Fine Sciences Shareholding Pattern

    Promoter
    49.1%
    Foreign Institutions
    2.9%
    Mutual Funds
    3.4%
    Domestic Institutions
    4.1%
    Public
    43.9%
    Promoter
    49.1%
    Foreign Institutions
    1.5%
    Mutual Funds
    3.5%
    Domestic Institutions
    3.8%
    Public
    45.6%
    Promoter
    48%
    Foreign Institutions
    0.8%
    Mutual Funds
    3.4%
    Domestic Institutions
    3.3%
    Public
    47.8%
    Promoter
    48%
    Foreign Institutions
    0.8%
    Mutual Funds
    4.2%
    Domestic Institutions
    4.2%
    Public
    46.9%
    Promoter
    48%
    Foreign Institutions
    1%
    Mutual Funds
    4.4%
    Domestic Institutions
    4.9%
    Public
    46.1%
    Promoter
    48%
    Foreign Institutions
    1.7%
    Mutual Funds
    2.8%
    Domestic Institutions
    4.5%
    Public
    45.7%

    Camlin Fine Sciences Technical Analysis

    Moving Averages Analysis
    210.50
    Current Price
    Bullish Moving Averages
    4
    Bearish Moving Averages
    12
    5Day EMA
    212.00
    10Day EMA
    224.40
    12Day EMA
    228.80
    20Day EMA
    242.50
    26Day EMA
    249.10
    50Day EMA
    255.00
    100Day EMA
    236.40
    200Day EMA
    201.30
    5Day SMA
    208.20
    10Day SMA
    227.80
    20Day SMA
    248.70
    30Day SMA
    263.90
    50Day SMA
    281.30
    100Day SMA
    233.80
    150Day SMA
    204.30
    200Day SMA
    183.00
    Delivery & Volume
    Loading chart...

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    332532 Rs
    332532 Rs
    Week Rs
    749549 Rs
    749549 Rs
    Month Rs
    433913 Rs
    433913 Rs
    206.93
    Pivot
    Resistance
    First Resistance
    209.87
    Second Resistance
    212.93
    Third Resistance
    215.87
    Support
    First Support
    203.87
    Second support
    200.93
    Third Support
    197.87
    Relative Strength Index
    26.06
    Money Flow Index
    79.21
    MACD
    -20.27
    MACD Signal
    -14.97
    Average True Range
    13.50
    Average Directional Index
    35.39
    Rate of Change (21)
    -29.32
    Rate of Change (125)
    46.33
    Name
    Holding Percent
    Franklin India Multi Cap Fund
    1.21
    ICICI Prudential Commodities Fund
    1.04

    Camlin Fine Sciences Latest News

    19 AUG 2025 | Tuesday

    Camlin Fine Sciences Ltd - 532834 - Announcement under Regulation 30 (LODR)-Newspaper Publication

    18 AUG 2025 | Monday

    Camlin Fine Sciences Ltd - 532834 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    13 AUG 2025 | Wednesday

    Camlin Fine Sciences Ltd - 532834 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    View More

    Camlin Fine Sciences Share Price FAQs

    Camlin Fine Sciences share price is ₹211.25 in NSE and ₹211.00 in BSE as on 20/8/2025.

    Camlin Fine Sciences share price in the past 1-year return was 106.25. The Camlin Fine Sciences share hit a 1-year low of Rs. 93.4 and a 1-year high of Rs. 333.3.

    The market cap of Camlin Fine Sciences is Rs. 3886.21 Cr. as of 20/8/2025.

    The PE ratios of Camlin Fine Sciences is 216.25 as of 20/8/2025.

    The PB ratios of Camlin Fine Sciences is 4.54 as of 20/8/2025

    The Mutual Fund Shareholding in Camlin Fine Sciences was 3.38% at the end of 20/8/2025.

    You can easily buy Camlin Fine Sciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Camlin Fine Sciences share price is ₹333.3 and ₹93.4 as of 20/8/2025.

    The earnings per share (EPS) of Camlin Fine Sciences declined at 0.5 during Q1 FY 2025-26.

    Please be aware that Camlin Fine Sciences stock prices are subject to continuous fluctuations due to various factors.

    Open Demat Account
    +91 -

    Popular Stocks
    60.10
    +0.51 (+0.86%)
    127.15
    +0.35 (+0.28%)
    691.65
    -8.60 (-1.23%)
    2,396.90
    +8.50 (+0.36%)
    149.03
    +0.12 (+0.08%)
    329.95
    +2.20 (+0.67%)
    162.02
    +2.79 (+1.75%)
    326.65
    +5.20 (+1.62%)
    374.00
    -6.05 (-1.59%)
    391.15
    +2.00 (+0.51%)
    Top Gainers
    1,486.70
    +46.70 (+3.24%)
    2,667.80
    +63.00 (+2.42%)
    3,087.00
    +70.80 (+2.35%)
    251.99
    +5.03 (+2.04%)
    327.80
    +6.35 (+1.98%)
    Top Losers
    887.35
    -14.95 (-1.66%)
    373.90
    -6.15 (-1.62%)
    616.65
    -9.70 (-1.55%)
    691.00
    -9.25 (-1.32%)
    5,432.00
    -64.00 (-1.16%)
    Open Demat Account
    +91 -